- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| 09:24 | SciBase: Nevisense Used in Fundamental Skin Barrier Research on Atopic Dermatitis | 158 | PR Newswire | STOCKHOLM, Sept. 26, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication... ► Artikel lesen | |
| Di | SciBase receives initial order for clinical study from Castle Biosciences | 214 | PR Newswire | STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has... ► Artikel lesen | |
| 10.09. | Main owners strengthen their position in SciBase | 216 | PR Newswire | STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that Ribbskottet... ► Artikel lesen | |
| 28.08. | SciBase: New Clinical Publication in Karger Dermatology Confirms Reader Studies as Key to Validating Nevisense | 228 | PR Newswire | STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces the recent publication... ► Artikel lesen | |
| 19.08. | SciBase: Interim report | 312 | PR Newswire | STOCKHOLM, Aug. 19, 2025 /PRNewswire/ --
January 1 - June 30, 2025
The second quarter in figures
Net sales were TSEK 8,791 (6,641), +32%, cleared for currency effects +40%.The... ► Artikel lesen | |
| 01.08. | SciBase announces outcome in directed share issue | 338 | PR Newswire | STOCKHOLM, Aug. 1, 2025 /PRNewswire/ -- On 16 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's Board of Directors resolved, pursuant to the authorisation... ► Artikel lesen | |
| 09.07. | SciBase Launches Nevisense Pilot at Leading University in Southeast Florida | 238 | PR Newswire | STOCKHOLM, July 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a... ► Artikel lesen | |
| 07.07. | SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense. | 282 | PR Newswire | STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce... ► Artikel lesen | |
| 30.06. | SciBase announces outcome in directed share issue | 187 | PR Newswire | STOCKHOLM, June 30, 2025 /PRNewswire/ -- On 23 June 2025, SciBase Holding AB (publ) ("SciBase" or the "Company") announced that the Company's board of directors resolved, pursuant to the... ► Artikel lesen | |
| 23.06. | SciBase resolves on a directed share issue of approximately SEK 11 million | 318 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 413 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 372 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 410 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com | ||
| 16.06. | Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 179 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it... ► Artikel lesen | |
| 09.06. | SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients | 312 | PR Newswire | STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch... ► Artikel lesen | |
| 04.06. | SciBase Expands Further Through European Market with First Sales Order to customer in Italy | 249 | PR Newswire | STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first... ► Artikel lesen | |
| 27.05. | SciBase reaches milestone with over 300,000 patients tested with Nevisense | 256 | PR Newswire | STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major... ► Artikel lesen | |
| 23.05. | SciBase publishes the Annual report for 2024 | 289 | PR Newswire | STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com.
A pdf-version of the annual report... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 84,49 | +0,52 % | Cathie Wood's ARK Sells Roku and Roblox, Buys Arcturus Stock | ||
| SERNOVA BIOTHERAPEUTICS | 0,111 | -2,63 % | Sernova Biotherapeutics Inc: Sernova Biotherapeutics appoints Brooks chairman | ||
| BOSTON SCIENTIFIC | 82,80 | 0,00 % | INFORMA MARKETS - ENGINEERING: Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions | BOSTON, MA / ACCESS Newswire / September 23, 2025 / MEDevice Boston, the premier MedTech event connecting top OEMs (Original Equipment Manufacturers) with emerging suppliers and strategic partners,... ► Artikel lesen | |
| PAUL HARTMANN | 228,00 | +0,88 % | Januar bis Juni 2025: PAUL HARTMANN behauptet sich in herausforderndem Marktumfeld | Heidenheim (ots) - - Umsatzerlöse steigen auf 1.214,0 Mio. EUR, organisches Umsatzwachstum von 1,6 % - Bereinigtes EBITDA liegt bei 125,8 Mio. EUR, bereinigte EBITDA-Rendite bei 10,4 % - Transformationsprogramm... ► Artikel lesen | |
| SYSMEX | 10,700 | -4,46 % | Sysmex Q1 Profit Declines | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Sysmex reported first quarter profit attributable to owners of the parent of 4.55 billion yen, down 58.7% from last year. Earnings per share was 7.30 yen... ► Artikel lesen | |
| ADDLIFE | 16,190 | -1,46 % | AddLife AB: Interim Report January 1 - June 30, 2025 | Continued improvement in margins and profit"The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development... ► Artikel lesen | |
| EMBECTA | 12,000 | +1,69 % | Analysts label Embecta 'undervalued' and poised for growth | ||
| ENOVIS | 26,800 | +3,88 % | Enovis Corporation: Enovis Announces Second Quarter 2025 Results | Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis Wilmington, DE, Aug. 07, 2025... ► Artikel lesen | |
| KANGJI MEDICAL | 0,935 | 0,00 % | KANGJI MEDICAL (09997): INTERIM REPORT 2025 | ||
| PULMONX | 1,470 | 0,00 % | Pulmonx korrigiert Umsatzprognose nach unten - US-Geschäft schwächelt | ||
| KOOTH | 1,610 | 0,00 % | Broker tips: Kooth, System1 | ||
| SI-BONE | 11,800 | 0,00 % | SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance | Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,670 | -2,19 % | PEIJIA-B (09996): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | ||
| BACTIGUARD | 1,755 | -2,50 % | Bactiguard Holding AB: Bactiguard Holding AB's interim report second quarter 2025 | Positive EBITDA momentum carried forward in Q2
Second quarter 2025 (April - June)
Total revenue amounted to SEK 52.1 (60.9) million, a decrease of SEK 8.8 million corresponding to 14.4%.
Net sales... ► Artikel lesen | |
| LIFECARE ASA | 0,888 | 0,00 % | Lifecare ASA: Lifecare strengthens miniaturisation roadmap with new patent applications |
Das Unternehmen SCIBASE HOLDING AB kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,010 Euro und damit -1,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.